4 results about "Octreotide" patented technology

The present invention provides a combination of two or more imaging agent conjugates comprising an imaging agent conjugated to a targeting ligand, wherein the imaging agent comprises one or more of: ZW800-1, ZW830-1, ZW700-1-Forte, ZW-DOTA, ZW-PyC3A, ZW-Macropa, ZW-Porphyrin, ZW-NOTA, and ZW-Deferoxamine; and the targeting ligand comprises one or more of: cRGD, dPSMA-617 or KUE, FAP, Bombesin Receptor Binding Vector, or Octreotide Binding Vector, or one or more of the peptides selected from SEQ ID Nos: 1 to 4.

The present invention provides a combination of two or more imaging agent conjugates comprising an imaging agent conjugated to a targeting ligand, wherein the imaging agent comprises one or more of ZW800-1, ZW830-1, ZW700-1-Forte, ZW-DOTA, ZW-PyC3A, ZW-Macropa, ZW-porphyrin, ZW-NOTA, and ZW-Deferoxamine; and the targeting ligand comprises one or more of a cRGD, a dPSMA-617 or a KUE, a FAP, a bombesin receptor binding vector, or a octreotide binding vector, or one or more of peptides selected from SEQ ID No: 1-4.

The present invention relates to a mixed green solvent based process for the preparation of peptide. More specifically, the present invention relates to a process of the preparation of Octreotide using greener solvent. The process of present invention also focused on minimizing solvent consumption, especially DMF, trifluoroacetic acid (TFA) and ethers. The process of present invention also substitutes acetonitrile with methanol in the chromatographic purification steps. The process of present invention only addresses environmental concerns associated with DMF usage but also maintains the efficiency and effectiveness of the Octreotide synthesis process.

The invention provides a preparation method of several < 68 > Ga labeled somatostatin receptor (SSTR) probes, and belongs to the technical field of nuclear medicine radiopharmaceuticals. The SSTR targeting compound octreotide is structurally modified by changing types and configurations of amino acids, changing disulfide bonds and increasing non-traditional amino acids on the basis of the existing SSTR targeting compound octreotide, and the series of probes have the advantages of good stability, high targeting property, higher tumor / normal tissue ratio (target / non-target ratio) and the like. The invention not only has a good application prospect in the aspect of PET / SPECT (positron emission tomography / single photon emission computed tomography) imaging agents of high-expression SSTR diseases, but also has potential advantages in the aspect of radioactive therapy of SSTR high-expression tumors.